Αποτελέσματα Αναζήτησης
10 Φεβ 2021 · The use of warfarin is declining with preference now being given to direct oral anticoagulants (DOACs) as first-line therapy in common anticoagulation indications, such as VTE treatment and prevention of recurrence, and stroke prevention in non-valvular atrial fibrillation (NVAF).
measures how much time it takes for your blood to clot and will determine if you’re receiving the right dose of warfarin. If your INR is too low, you could be at risk for a blood clot – but if it’s too high, you could experience bleeding. A typical INR target ranges from 2-3 but can vary from patient to patient.
For most indications, the therapeutic INR range is 2.0 to 3.0. Exceptions are when war-farin is used for secondary prevention after a myocardial infarction or for patients with high-risk mechanical prosthetic heart valves, in which case the range is 2.5 to 3.5.
If the baseline INR≤1.3 the patient will receive 5mg of warfarin once daily on days 1 and 2. The INR is checked on day 3 and 4 and the warfarin dose is adjusted according to the schedule.
This guideline outlines the evidence for managing anticoagulation therapy with oral vitamin K antagonist (warfarin). For dosing and monitoring of warfarin therapy it is recommended that standardized and validated decision support tools be used for most patients.
Initial warfarin dosing should be tailored based on baseline INR, patient bleed risk, potential sensitivity to warfarin, indication, goal INR range and if potential drug interactions are present 1 (UW Health GRADE high quality evidence, S recommendation)
Interpreting PT/INR results can be confusing. For patients with a history of valve replacement or AFIB, the goal is to maintain a therapeutic range of between 2.0 to 3. Excessive clotting or blood that is too thick can cause a stroke while blood that is too thin makes it difficult for the body stop.
